List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8621690/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Population Pharmacokinetic Modeling and Optimal Sampling Strategy for Bayesian Estimation of Amikacin Exposure in Critically III Septic Patients. Therapeutic Drug Monitoring, 2010, 32, 749-756.	2.0	594
2	Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. European Journal of Clinical Pharmacology, 2008, 64, 1147-1161.	1.9	518
3	Pharmacokinetics and dosage adjustment in patients with renal dysfunction. European Journal of Clinical Pharmacology, 2009, 65, 757-773.	1.9	392
4	Clinical Pharmacokinetics of Non-steroidal Anti-inflammatory Drugs. Clinical Pharmacokinetics, 1983, 8, 297-331.	3.5	205
5	Comparative Clinical Pharmacokinetics of Tacrolimus in Paediatric and Adult Patients. Clinical Pharmacokinetics, 2001, 40, 283-295.	3.5	124
6	Plasma Protein Binding of Drugs in the Elderly. Clinical Pharmacokinetics, 1987, 12, 41-72.	3.5	120
7	Effects of age and sex on piroxicam disposition. Clinical Pharmacology and Therapeutics, 1985, 37, 13-18.	4.7	88
8	Pharmacokinetic Drug Interactions with Nonsteroidal Anti-Inflammatory Drugs. Clinical Pharmacokinetics, 1990, 19, 44-66.	3.5	87
9	Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. Journal of Pharmaceutical Sciences, 2003, 92, 938-950.	3.3	84
10	The Effect of Ageing on Cytochrome P450 Enzymes: Consequences for Drug Biotransformation in the Elderly. Current Medicinal Chemistry, 2007, 14, 745-757.	2.4	75
11	Biotransformation of diflunisal and renal excretion of its glucuronides in renal insufficiency British Journal of Clinical Pharmacology, 1979, 7, 273-282.	2.4	74
12	Extrahepatic glucuronidation of propofol in man: possible contribution of gut wall and kidney. European Journal of Clinical Pharmacology, 1996, 50, 91-96.	1.9	73
13	Blood microdialysis in pharmacokinetic and drug metabolism studies. Advanced Drug Delivery Reviews, 2000, 45, 217-228.	13.7	73
14	BIOTRANSFORMATION AND EXCRETION OF LORAZEPAM IN PATIENTS WITH CHRONIC RENAL FAILURE. British Journal of Clinical Pharmacology, 1976, 3, 1033-1039.	2.4	65
15	Drug Metabolites in Renal Failure. Clinical Pharmacokinetics, 1981, 6, 329-345.	3.5	61
16	The effect of endâ€stage renal failure and haemodialysis on the elimination kinetics of sotalol British Journal of Clinical Pharmacology, 1976, 3, 259-265.	2.4	60
17	Application of dermal microdialysis for the evaluation of bioequivalence of a ketoprofen topical gel. European Journal of Pharmaceutical Sciences, 2009, 36, 219-225.	4.0	60
18	Furosemide kinetics and dynamics in patients with cirrhosis. Clinical Pharmacology and Therapeutics, 1986, 40, 14-20.	4.7	58

ROGER K VERBEECK

#	Article	lF	CITATIONS
19	Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring. European Journal of Clinical Pharmacology, 2016, 72, 905-916.	1.9	58
20	Excretion of trazodone in breast milk British Journal of Clinical Pharmacology, 1986, 22, 367-370.	2.4	57
21	Binding of phenothiazine neuroleptics to plasma proteins. Biochemical Pharmacology, 1983, 32, 2565-2570.	4.4	54
22	Limited Sampling Models and Bayesian Estimation for Mycophenolic Acid Area under the Curve Prediction in Stable Renal Transplant Patients Co-Medicated with Ciclosporin or Sirolimus. Clinical Pharmacokinetics, 2009, 48, 745-758.	3.5	52
23	Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride**This study reflects the scientific opinion of the authors and not the policies of regulating agencies lournal of Pharmaceutical Sciences. 2005. 94. 1389-1395.	3.3	48
24	Intravenous microdialysis in the mouse and the rat: development and pharmacokinetic application of a new probe. Pharmaceutical Research, 1996, 13, 12-17.	3.5	47
25	Role of taurine in osmoregulation during endurance exercise. European Journal of Applied Physiology, 2002, 87, 489-495.	2.5	47
26	Furosemide disposition in cirrhosis. Clinical Pharmacology and Therapeutics, 1982, 31, 719-725.	4.7	45
27	Fluconazole Distribution in Rat Dermis Following Intravenous and Topical Application: A Microdialysis Study. Journal of Pharmaceutical Sciences, 2005, 94, 770-780.	3.3	42
28	Meperidine disposition in man: Influence of urinary pH and route of administration. Clinical Pharmacology and Therapeutics, 1981, 30, 619-628.	4.7	41
29	Prediction of paraquat exposure and toxicity in clinically ill poisoned patients: a model based approach. British Journal of Clinical Pharmacology, 2014, 78, 855-866.	2.4	39
30	Reduced elimination of ketoprofen in the elderly is not necessarily due to impaired glucuronidation British Journal of Clinical Pharmacology, 1984, 17, 783-784.	2.4	38
31	On-line determination of fluconazole in blood and dermal rat microdialysates by microbore high-performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 787, 323-331.	2.3	38
32	Sensitive assay for midazolam and its metabolite 1′-hydroxymidazolam in human plasma by capillary high-performance liquid chromatography. Biomedical Applications, 1998, 710, 165-171.	1.7	36
33	Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians. Clinical Infectious Diseases, 2017, 64, 104-105.	5.8	36
34	Sex-difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal. European Journal of Clinical Pharmacology, 1990, 38, 175-9.	1.9	35
35	A Simultaneous Dâ€Optimal Designed Study for Population Pharmacokinetic Analyses of Mycophenolic Acid and Tacrolimus Early After Renal Transplantation. Journal of Clinical Pharmacology, 2012, 52, 1833-1843.	2.0	35
36	High-performance liquid chromatographic analysis of piroxicam and its major metabolite 5′-hydroxypiroxicam in human plasma and urine. Biomedical Applications, 1986, 382, 382-388.	1.7	34

#	Article	IF	CITATIONS
37	Propofol pharmacokinetics in children with biliary atresia. British Journal of Anaesthesia, 1995, 74, 46-49.	3.4	34
38	Cryopreservation of rat precision-cut liver slices by ultrarapid freezing. Life Sciences, 2001, 68, 2391-2403.	4.3	34
39	Differential Activities of CYP1A Isozymes in Hepatic and Intestinal Microsomes of Control and 3-Methylcholanthrene-Induced Rats. Basic and Clinical Pharmacology and Toxicology, 2000, 86, 71-77.	0.0	34
40	Age-related changes in the protein and mRNA levels of CYP2E1 and CYP3A isoforms as well as in their hepatic activities in Wistar rats. What role for oxidative stress?. Archives of Toxicology, 2004, 78, 131-138.	4.2	33
41	Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: single dose studies British Journal of Clinical Pharmacology, 1988, 26, 31-39.	2.4	31
42	Effect of aluminum hydroxide on diflunisal absorption British Journal of Clinical Pharmacology, 1979, 7, 519-522.	2.4	30
43	Simultaneous microdialysis in brain and blood of the mouse: extracellular and intracellular brain colchicine disposition. Brain Research, 1998, 786, 122-127.	2.2	30
44	Application of Dermal Microdialysis for the Determination of Bioavailability of Clobetasol Propionate Applied to the Skin of Human Subjects. Skin Pharmacology and Physiology, 2012, 25, 17-24.	2.5	30
45	Evaluation of the formalin test to assess the analgesic activity of diflunisal in the rat. European Journal of Pharmaceutical Sciences, 1998, 6, 307-312.	4.0	29
46	Modulation of paracetamol metabolism by Kupffer cells: A study on rat liver slices. Life Sciences, 1999, 65, 2851-2859.	4.3	29
47	Time of Drug Administration, CYP3A5 and ABCB1 Genotypes, and Analytical Method Influence Tacrolimus Pharmacokinetics: A Population Pharmacokinetic Study. Therapeutic Drug Monitoring, 2009, 31, 734-742.	2.0	29
48	Population pharmacokinetics of four \hat{l}^2 -lactams in critically ill septic patients comedicated with amikacin. Clinical Biochemistry, 2012, 45, 780-786.	1.9	29
49	Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation. European Journal of Clinical Pharmacology, 2013, 69, 1533-1542.	1.9	29
50	Glucuronidation of diflunisal by rat liver microsomes. Biochemical Pharmacology, 1993, 46, 1953-1958.	4.4	28
51	Circadian rhythm of serum sulfate levels in man and acetaminophen pharmacokinetics. European Journal of Clinical Pharmacology, 1990, 39, 143-148.	1.9	27
52	Differential induction of midazolam metabolism in the small intestine and liver by oral and interation in rat. Xenobiotica, 2002, 32, 975-984.	1.1	27
53	The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action. Journal of Pharmacy and Pharmaceutical Sciences, 2012, 15, 376.	2.1	27
54	Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Enalapril. Journal of Pharmaceutical Sciences, 2017, 106, 1933-1943.	3.3	27

#	Article	IF	CITATIONS
55	Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding. Clinical Pharmacology and Therapeutics, 1980, 27, 628-635.	4.7	26
56	ELIMINATION OF DIFLUNISAL AS ITS ACYL GLUCURONIDE, PHENOLIC GLUCURONIDE AND SULFATE CONJUGATES IN BILE-EXTERIORIZED AND INTACT RATS. Clinical and Experimental Pharmacology and Physiology, 1989, 16, 913-924.	1.9	25
57	Concentration-dependent plasma protein binding of flurbiprofen in the rat: an in vivo microdialysis study. Pharmaceutical Research, 1996, 13, 18-22.	3.5	25
58	In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat. Pharmaceutical Research, 1996, 13, 891-895.	3.5	25
59	Statistical tools for dose individualization of mycophenolic acid and tacrolimus coâ€administered during the first month after renal transplantation. British Journal of Clinical Pharmacology, 2013, 75, 1277-1288.	2.4	25
60	Plasma protein binding and interaction studies with diflunisal, a new salicylate analgesic. Biochemical Pharmacology, 1980, 29, 571-576.	4.4	24
61	Kinetics of oral trifluoperazine disposition in man British Journal of Clinical Pharmacology, 1983, 15, 380-382.	2.4	24
62	High-Performance Liquid Chromatographic Method for the Simultaneous Quantitation of Diflunisal and its Glucuronide and Sulfate Conjugates in Human Urine. Journal of Pharmaceutical Sciences, 1989, 78, 250-255.	3.3	24
63	Population Pharmacokinetic Analysis of Tacrolimus Early After Pediatric Liver Transplantation. Therapeutic Drug Monitoring, 2014, 36, 54-61.	2.0	24
64	Glucuronidation of diflunisal in liver and kidney microsomes of rat and man. Xenobiotica, 1996, 26, 123-131.	1.1	22
65	In vivo Tolerance Assessment of Skin after Insertion of Subcutaneous and Cutaneous Microdialysis Probes in the Rat. Skin Pharmacology and Physiology, 2003, 16, 18-27.	2.5	22
66	Midazolam and cortisol metabolism before and after CYP3A induction in humans. International Journal of Clinical Pharmacology and Therapeutics, 2001, 39, 293-299.	0.6	22
67	The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man British Journal of Clinical Pharmacology, 1990, 29, 381-389.	2.4	21
68	Piroxicam and 5?-hydroxypiroxicam kinetics following multiple dose administration of piroxicam. European Journal of Clinical Pharmacology, 1987, 32, 89-91.	1.9	20
69	Ageing is associated with increased expression but decreased activity of CYP2E1 in male Wistar rats. Life Sciences, 2006, 79, 1913-1920.	4.3	20
70	Empirical models for dosage optimization of four β-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin. Clinical Biochemistry, 2010, 43, 589-598.	1.9	20
71	In children, the addition of epinephrine modifies the pharmacokinetics of ropivacaine injected caudally. Canadian Journal of Anaesthesia, 2003, 50, 593-598.	1.6	19
72	Conjugation-deconjugation cycling of diflunisal via β-glucuronidase catalyzed hydrolysis of its acyl glucuronide in the rat. Life Sciences, 1997, 60, 2013-2021.	4.3	18

#	Article	IF	CITATIONS
73	Validation of subcutaneous microdialysis sampling for pharmacokinetic studies of flurbiprofen in the rat. Journal of Pharmaceutical Sciences, 2001, 90, 1897-1906.	3.3	18
74	Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis. European Journal of Clinical Pharmacology, 1992, 42, 471-474.	1.9	17
75	Study of the Percutaneous Penetration of Flurbiprofen by Cutaneous and Subcutaneous Microdialysis after Iontophoretic Delivery in Rat. Journal of Pharmaceutical Sciences, 2005, 94, 144-152.	3.3	16
76	Diflunisal and its conjugates in patients with renal failure British Journal of Clinical Pharmacology, 1991, 31, 546-550.	2.4	15
77	Glucuronidation kinetics of R,S-ketoprofen in adjuvant-induced arthritic rats. Pharmaceutical Research, 1999, 16, 1081-1086.	3.5	15
78	Biliary excretion of diflunisal conjugates in patients with T-tube drainage. European Journal of Clinical Pharmacology, 1988, 34, 423-426.	1.9	14
79	Excretion of tacrolimus glucuronides in human bile. European Journal of Drug Metabolism and Pharmacokinetics, 1997, 22, 217-221.	1.6	13
80	A Rapid High-Performance Liquid Chromatographic Method for the Measurement of Midazolam Plasma Concentrations During Long-Term Infusion in ICU Patients. Therapeutic Drug Monitoring, 1997, 19, 352-357.	2.0	13
81	Predictors of tuberculosis treatment success under the DOTS program in Namibia. Expert Review of Respiratory Medicine, 2018, 12, 979-987.	2.5	12
82	Effect of probenecid on the formation and elimination kinetics of the sulphate and glucuronide conjugates of diflunisal. European Journal of Clinical Pharmacology, 1995, 47, 519-23.	1.9	11
83	The use of precision-cut liver slices from male Wistar rats as a tool to study age related changes in CYP3A induction and in formation of paracetamol conjugates. Toxicology in Vitro, 2004, 18, 879-885.	2.4	11
84	Alfentanil-Induced Miosis as a Surrogate Measure of Alfentanil Pharmacokinetics in Patients with Mild and Moderate Liver Cirrhosis. Clinical Pharmacokinetics, 2007, 46, 261-270.	3.5	11
85	Decreased CYP3A2 expression and activity in senescent male Wistar rats: Is there a role for HNF4α?. Experimental Gerontology, 2006, 41, 846-854.	2.8	10
86	Comparative oral bioavailability of non-fixed and fixed combinations of artesunate and amodiaquine in healthy Indian male volunteers. European Journal of Clinical Pharmacology, 2011, 67, 267-275.	1.9	9
87	Assessment of anticoagulation management in outpatients attending a warfarin clinic in Windhoek, Namibia. Drugs and Therapy Perspectives, 2019, 35, 341-346.	0.6	9
88	Cryopreservation of Rat Precision-cut Liver Slices is Associated with Major Metabolic Stress and Ionic Perturbations. Cellular Physiology and Biochemistry, 2003, 13, 103-112.	1.6	8
89	Predictors of loss to follow-up of tuberculosis cases under the DOTS programme in Namibia. ERJ Open Research, 2020, 6, 00030-2019.	2.6	8
90	Trazodone Hydrochloride. Analytical Profiles of Drug Substances, 1987, , 693-730.	0.0	7

6

ROGER K VERBEECK

#	Article	IF	CITATIONS
91	Isolation and identification of new rapamycin dihydrodiol metabolites from dexamethasoneinduced rat liver microsomes. Xenobiotica, 1997, 27, 869-883.	1.1	7
92	Isolation and identification of a C39 demethylated metabolite of rapamycin from pig liver microsomes and evaluation of its immunosuppressive activity. Clinical Chemistry, 1998, 44, 532-538.	3.2	6
93	Alfentanil-Induced Miosis Clearance as a Liver CYP3A4 and 3A5 Activity Measure in Healthy Volunteers: Improvement of Experimental Conditions. Journal of Clinical Pharmacology, 2005, 45, 1434-1441.	2.0	6
94	The Lidose Hard Capsule Formulation of Fenofibrate is Suprabioavailable Compared to the Nanoparticle Tablet Formulation Under High-fat Fed Conditions. Journal of Pharmacy and Pharmaceutical Sciences, 2015, 18, 61.	2.1	6
95	GLUCURONIDATION OF DIFLUNISAL, (â^')-MORPHINE, 4-NITROPHENOL, AND PROPOFOL IN LIVER MICROSOMES OF TWO PATIENTS WITH CRIGLER–NAJJAR SYNDROME TYPE I. , 1996, 17, 311-317.		4
96	Induction of CYP2C12 expression in senescent male rats is well correlated to an increase of HNF3Î ² expression, while the decline of CYP2C11 expression is unlikely due to a decrease of STAT5 activation. Biochemical Pharmacology, 2007, 73, 923-933.	4.4	4
97	Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects. European Journal of Drug Metabolism and Pharmacokinetics, 2012, 37, 125-132.	1.6	4
98	Clinical Significance of the Plasma Protein Binding of Rifampicin in the Treatment of Tuberculosis Patients. Clinical Pharmacokinetics, 2019, 58, 1511-1515.	3.5	3
99	Should Codeine Still be Considered a WHO Essential Medicine?. Journal of Pharmacy and Pharmaceutical Sciences, 2021, 24, 329-335.	2.1	2
100	Monitoring of gentamicin serum concentrations in obstetrics and gynaecology patients in Namibia. International Journal of Clinical Pharmacy, 2018, 40, 520-525.	2.1	1
101	Differential Activities of CYP1A Isozymes in Hepatic and Intestinal Microsomes of Control and 3-Methylcholanthrene-Induced Rats. Basic and Clinical Pharmacology and Toxicology, 2008, 86, 71-77.	0.0	0
102	CYP1A1 but Not CYP1A2 Proteins are Expressed in Human Lymphocytes. Basic and Clinical Pharmacology and Toxicology, 2008, 86, 242-244.	0.0	0
103	Validation of subcutaneous microdialysis sampling for pharmacokinetic studies of flurbiprofen in the rat. Journal of Pharmaceutical Sciences, 2001, 90, 1897-1906.	3.3	0
104	Pharmacokinetic Considerations in the Toxicologic Evaluation of Xenobiotics. , 1995, , 125-144.		0